161 related articles for article (PubMed ID: 36029387)
21. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
[TBL] [Abstract][Full Text] [Related]
22. The atypical CDK activator Spy1 regulates the intrinsic DNA damage response and is dependent upon p53 to inhibit apoptosis.
McAndrew CW; Gastwirt RF; Donoghue DJ
Cell Cycle; 2009 Jan; 8(1):66-75. PubMed ID: 19106603
[TBL] [Abstract][Full Text] [Related]
23. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
24. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
25. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
26. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
27. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
28. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
[TBL] [Abstract][Full Text] [Related]
29. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
31. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract][Full Text] [Related]
32. Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
Kilker RL; Planas-Silva MD
Cancer Res; 2006 Dec; 66(23):11478-84. PubMed ID: 17145896
[TBL] [Abstract][Full Text] [Related]
33. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
34. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells.
Yin S; Cheryan VT; Xu L; Rishi AK; Reddy KB
PLoS One; 2017; 12(8):e0183578. PubMed ID: 28817737
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
[TBL] [Abstract][Full Text] [Related]
36. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
38. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
39. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
Park SH; Chung YM; Ma J; Yang Q; Berek JS; Hu MC
Oncotarget; 2016 Jul; 7(27):42110-42125. PubMed ID: 27283899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]